Posts by Keith T. Flaherty, MD
-
37 Biopsies, Nine Years: Mapping Evolution of Resistance to Melanoma Immunotherapy in a Former Complete Responder
Genevieve Boland, MD, PhD, Keith Flaherty, MD, and colleagues analyzed tumor samples over the entire clinical course of a patient with metastatic melanoma, providing insights into tumor microenvironmental changes that occurred when he became resistant to immune checkpoint inhibition after a previous complete response.
-
Capivasertib Shows Promise Against Refractory AKT-mutated Tumors
Keith Flaherty, MD, director of clinical research at the Massachusetts General Hospital Cancer Center, and colleagues found that capivasertib has meaningful activity in patients with various refractory AKT1 E17K-mutated tumors, including triple-negative breast cancer and rare cancers.
-
Medical Grand Rounds: Advancing New Therapies for COVID-19: Antiviral, Immunomodulation and Beyond
On April 9, 2020, the Department of Medicine held its fifth virtual Grand Rounds presentation related to COVID-19. Keith Flaherty, MD, at Massachusetts General Hospital, and Scott Gottlieb, MD, former FDA commissioner, along with other members of the Greater Boston medical community, presented on advancing experimental therapies to treat COVID-19.
-
Mass General Takes Platform Approach to COVID-19 Clinical Trials
Mass General has launched a COVID-19 clinical trials platform that pairs its infectious disease and immunology experts with organ-specific physiology and clinical care leaders to rapidly implement and conduct new investigator- and industry-initiated clinical trials.
Biography
Dr. Keith Flaherty is the director of the Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
